A literature review published in JMCP found mixed evidence regarding the use of pharmacogenomic testing to guide cancer treatment. Prioritization of clinically relevant drug-gene associations is critical in determining which tests are beneficial.
Partnership Forum: Implementing value-based reimbursement models for both pharmaceuticals and medical care poses significant challenges and opportunities, and depends on integrated delivery networks (IDNs) to execute the processes and programs. Industry thought leaders convened to discuss the issues.
Partnership Forum: AMCP defined the ideal state for PROs , their importance and systems needed in a previous forum. Here AMCP brought together thought leaders to discuss and identify tactics to achieve the “ideal state.”
Press Release: Thought leaders representing managed care organizations, providers, patients, biopharmaceutical manufacturers and other stakeholders gathered recently to find solutions to the financial burden of oncology care on patients, while also improving cancer treatment outcomes and advancing the concept of value-based health care.